Parathyroid gland

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Retrieved on: 
Monday, September 12, 2022
Osteoporosis, Tablet, Gastrointestinal tract, PTH, Woman, BMD, Blood, American Society for Bone and Mineral Research, Poster, Society, Parathyroid hormone, Oral, Menopause, Organic acid, NASDAQ, Calcium, Teriparatide, Parathyroid gland, GLOBE, R, Kidney, Plasma, Pharmaceutical industry, Medical imaging, Entera, Osteocalcin

These new analyses of blood hPTH concentration shortly after a dose of oral EB613 tablets confirm a strong, statistically significant correlation between mean blood level and the dose of EB613 taken.

Key Points: 
  • These new analyses of blood hPTH concentration shortly after a dose of oral EB613 tablets confirm a strong, statistically significant correlation between mean blood level and the dose of EB613 taken.
  • This finding is consistent with excellent correlation between change in lumbar spine BMD and dose of EB613 after 6 months of treatment, Said Dr. Arthur Santora, Chief Medical Officer at Entera.
  • We are encouraged by this important correlation analysis from our positive phase 2 study of EB613.
  • The most recent study was a dose ranging Phase 2 study in postmenopausal women with low bone mass.

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

Retrieved on: 
Thursday, August 11, 2022
FDA, Teriparatide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Woman, Endocrinology, Gastrointestinal tract, GLOBE, R, Hypoparathyroidism, Clinical trial, Bone, Coronavirus Scientific Advisory Board (Turkey), D&O, Patent, Society, Research, FNIH, Vitamin D, Patient, Parathyroid hormone, Company, American Society for Bone and Mineral Research, Protein, Organic acid, NASDAQ, Parathyroid gland, Lists of diseases, BMD, Maintenance, Kidney, Calcium, Insurance, Type, Consultant, Food, Osteoporosis, CSAB, Disease, PTH, Pharmaceutical industry, Online gambling, Osteocalcin, Amgen, Entera

JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (Entera or the Company) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022.

Key Points: 
  • JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (Entera or the Company) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022.
  • Entera expects to hold a Type C Meeting with the FDA to discuss the potential registrational study for its lead clinical asset, EB613 in the second half of 2022.
  • Entera expects that the current cash is sufficient to fund the operations through the second quarter of 2023.
  • Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release.

1 in 50 Women Will Suffer From Parathyroid Disease

Retrieved on: 
Wednesday, July 6, 2022
People, Well, Kidney failure, Diagnosis, Surgeon, View, Patient, Arrhythmia, Heart, Hyperparathyroidism, Research, University, Tissue, Brain, Parathyroid gland, Anatomy, Chronic fatigue, Element, Blood, Disease, Mark (given name), Neck, Depression, Gastrointestinal tract, Calcium, Endocrine system, Human body, Kidney, Woman, Risk, Cancer, Parathyroid disease, Neoplasm, Exocrine gland, Parathyroid hormone, Busch Gardens, Human, Mammal, Hospital, Headache, Hypertension, Osteoporosis, Amnesia, PTH, Bone pain, Muscle, Eating, Multimedia, Medical imaging, Phosphorus, Pharmaceutical industry, Dentistry, EU

Hyperparathyroidism (parathyroid disease) is the most common condition of parathyroid glands, caused by the development of a tumor on one or more parathyroid glands.

Key Points: 
  • Hyperparathyroidism (parathyroid disease) is the most common condition of parathyroid glands, caused by the development of a tumor on one or more parathyroid glands.
  • In fact, the Norman Parathyroid Center cites that 1 in 50 women will suffer from parathyroid disease at some point in their lives.
  • The surgeons at the Norman Parathyroid Center are by far the most experienced parathyroid surgeons in the world performing 70+ parathyroid operations per week.
  • Located in Tampa, Florida, the Norman Parathyroid Center is the leading parathyroid gland tumor treatment center in the world, performing nearly 3,800 parathyroid operations annually.

Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates

Retrieved on: 
Wednesday, August 4, 2021
Hormones, Endocrine system, Glands, Parathyroid gland, Parathyroid hormone, PTH

TORONTO, ONTARIO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2021. The Company also provided an update on its pre-clinical and clinical development programs.

Key Points: 
  • TORONTO, ONTARIO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2021.
  • In consultation with The University of Sheffield, UK, selected AEZS-150 as the lead candidate in the Company's delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program.
  • In February 2021, Aeterna entered into an exclusive option agreement with Julius-Maximilians-University to evaluate a preclinical, potential COVID-19 vaccine developed at Julius-Maximilians-University.
  • The Company had $69.9 million cash and cash equivalents at June 30, 2021 (March 31, 2021 73.4 million).

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

Retrieved on: 
Monday, June 28, 2021
Hormones, Branches of biology, Endocrine system, Glands, Parathyroid gland, Osteoporosis, Parathyroid hormone

EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.

Key Points: 
  • EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.
  • Dr. Tripto-Shkolnik will provide context on the results of the study and the benefits of an oral drug to treat osteoporosis.
  • The conference call will take place on Wednesday, June 30, 2021 from 12-1pm EDT and will include a question-and-answer session.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

Retrieved on: 
Friday, May 28, 2021
Rare diseases, Anatomy, Medical specialties, Branches of biology, Electrolyte disturbances, Glands, Parathyroid gland, Hypoparathyroidism, Parathyroid hormone, Hypocalcemia, Endocrine system, Endocrine disease

The live, online event seeks to raise awareness of hypoparathyroidism worldwide and share Ariana Feiners uplifting message of hope and inspiration to those affected by chronic illness.

Key Points: 
  • The live, online event seeks to raise awareness of hypoparathyroidism worldwide and share Ariana Feiners uplifting message of hope and inspiration to those affected by chronic illness.
  • Hypoparathyroidism (HP) is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH), resulting in low calcium and elevated phosphate levels in the blood.
  • Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development.
  • Ascendis,Ascendis Pharma, theAscendis Pharmalogo, the company logo and TransCon are trademarks owned by theAscendis Pharma Group.

Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences

Retrieved on: 
Tuesday, May 18, 2021
Anatomy, Branches of biology, Organ systems, Endocrine system, Rare diseases, Glands, Parathyroid gland, Kidney, Hypoparathyroidism, Glucose

In addition, Amolyt will present two retrospective Natural History Study methods to identify patients with chronic hypoparathyroidism.

Key Points: 
  • In addition, Amolyt will present two retrospective Natural History Study methods to identify patients with chronic hypoparathyroidism.
  • Finally, Amolyt will present preclinical data for AZP-3404, a peptide with a new and unique potential mechanism of action on fat and glucose metabolism.
  • At ISPOR 2021, Amolyt will present proposed methods to identify patients with chronic hypoparathyroidism using claims data in the United States (US).
  • Clinical manifestations of hypoparathyroidism vary and impact a large number of tissues and organ systems, including the muscles, brain, heart, and kidneys.

Neeta Erinjeri, MD is recognized by Continental Who's Who

Retrieved on: 
Tuesday, April 20, 2021
Medical specialties, Surgical specialties, Clinical medicine, Medicine, Endocrine surgery, General surgery, Otorhinolaryngology, Endocrine system, Parathyroid gland, Julie Ann Sosa

Patients are offered precise, personalized treatment plans that incorporate groundbreaking discoveries and collaborations with other world-renowned cancer researchers.

Key Points: 
  • Patients are offered precise, personalized treatment plans that incorporate groundbreaking discoveries and collaborations with other world-renowned cancer researchers.
  • She specializes in the endocrine system, providing surgery on the thyroid, parathyroid, and adrenal glands.
  • Following graduation, she went on to obtain his Medical degree from Michigan State University School of Medicine.
  • She completed a General Surgery residency, and endocrine surgery fellowship at Yale School of Medicine (New Haven Hospital).

Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021

Retrieved on: 
Tuesday, March 23, 2021
Branches of biology, Hormones, Rare diseases, Glands, Calcium, Parathyroid hormone, Hypoparathyroidism, Hypocalcemia, Parathyroid gland, Tolerability

Importantly, we are presenting the first data on the treatment effect of TransCon PTH on the Hypoparathyroidism Patient Experience Scale (HPES).

Key Points: 
  • Importantly, we are presenting the first data on the treatment effect of TransCon PTH on the Hypoparathyroidism Patient Experience Scale (HPES).
  • Presentation title:TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension in 58 subjects.
  • TransCon PTH continues to be well-tolerated:
    No adverse events of hypocalcemia or hypercalcemia requiring visit to hospital, emergency room or urgent care.
  • In addition, to PaTH Forward, Ascendis Pharma is conducting the PaTHway Trial, a phase 3 clinical study evaluating the safety, tolerability and efficacy of TransCon PTH in adults with HP.

Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021

Retrieved on: 
Tuesday, March 16, 2021
Anatomy, Branches of biology, Glands, Rare diseases, Parathyroid hormone, Endocrine system, Parathyroid gland, Hypoparathyroidism, Thyroid, Parathyroidectomy

Amolyt will present preliminary data from its Phase 1 clinical trial evaluating AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, in addition to two abstracts detailing a retrospective natural history study of chronic hypoparathyroidism.

Key Points: 
  • Amolyt will present preliminary data from its Phase 1 clinical trial evaluating AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, in addition to two abstracts detailing a retrospective natural history study of chronic hypoparathyroidism.
  • Amolyt will also present preclinical data for AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.
  • Hypoparathyroidism is defined by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and elevated phosphorus levels in the blood.
  • Clinical manifestations of hypoparathyroidism vary and impact a large number of tissues and organ systems, including the muscles, brain, heart, and kidneys.